These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 10928150)
1. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150 [TBL] [Abstract][Full Text] [Related]
2. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296 [TBL] [Abstract][Full Text] [Related]
3. Clinical applications of the histoculture drug response assay. Furukawa T; Kubota T; Hoffman RM Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788 [TBL] [Abstract][Full Text] [Related]
6. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475 [TBL] [Abstract][Full Text] [Related]
7. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793 [TBL] [Abstract][Full Text] [Related]
8. Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer. Adachi S; Itani Y; Ito K; Noda T; Shintani M; Saito K; Furukawa N; Tomii Y Oncol Rep; 2001; 8(1):27-31. PubMed ID: 11115564 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769 [TBL] [Abstract][Full Text] [Related]
10. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226 [TBL] [Abstract][Full Text] [Related]
11. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460 [TBL] [Abstract][Full Text] [Related]
12. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I. Mäenpää J; Kangas L; Grönroos M Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908 [TBL] [Abstract][Full Text] [Related]
13. Prospective Clinical Correlation of the Histoculture Drug Response Assay for Ovarian Cancer. Hoffman RM; Jung PS; Kim MB; Nam JH Methods Mol Biol; 2018; 1760():73-81. PubMed ID: 29572795 [TBL] [Abstract][Full Text] [Related]
14. Sequential high dose-density chemotherapy in advanced ovarian cancer. Tognoni A; Pronzato P; Cadenotti L; Ghio E; Manna N; Pensa F; Marino L Anticancer Res; 2000; 20(5C):3957-61. PubMed ID: 11268483 [TBL] [Abstract][Full Text] [Related]
15. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation]. Gao KF; Liu FY; Chen FJ; Feng YL Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668 [TBL] [Abstract][Full Text] [Related]
16. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma. Ezawa S; Suzuki N; Ohie S; Higashiguchi A; Hosoi F; Kitazato K; Susumu N; Aoki D Gynecol Oncol; 2008 Mar; 108(3):627-31. PubMed ID: 18048092 [TBL] [Abstract][Full Text] [Related]
17. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP; J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437 [TBL] [Abstract][Full Text] [Related]
18. [Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer--a case report]. Tanino H; Miyoshi S; Furukawa T; Bessho T; Maebeya S; Suzuma T; Hirai I; Arimoto J; Harada N; Hoso T; Naito Y Gan To Kagaku Ryoho; 1997 May; 24(7):861-4. PubMed ID: 9170526 [TBL] [Abstract][Full Text] [Related]
19. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Kubota T; Sasano N; Abe O; Nakao I; Kawamura E; Saito T; Endo M; Kimura K; Demura H; Sasano H Clin Cancer Res; 1995 Dec; 1(12):1537-43. PubMed ID: 9815954 [TBL] [Abstract][Full Text] [Related]
20. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer]. Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]